Navigation Links
Pfenex Inc. and Agila Biotech Private Limited Announce Joint Venture to Develop Biosimilar Products for the Global Market
Date:4/16/2013

SAN DIEGO and BANGALORE, India, April 16, 2013 /PRNewswire/ -- Pfenex Inc. and Agila Biotech Private Limited, a subsidiary of Strides Arcolab Limited today announced that they have entered into a joint venture to develop, manufacture and commercialize an initial pipeline of six biosimilar products for the global market. Operating as a JV, wherein both parties will equally share in decision making regarding product development and commercialization, Agila Biotech will be a 51% equity stakeholder.  This multi-product joint venture combines Pfenex's industry-leading expertise in strain engineering and process development with Agila Biotech's biologics manufacturing and clinical development excellence. The lead product for the joint venture is Interferon beta-1b, a biosimilar to Betaseron®, indicated for relapsing-remitting and secondary-progressive forms of multiple sclerosis, commencing human clinical trials by Q4 2013.  Under the terms of the agreement, Pfenex will assume primary responsibility for development of  an optimized production strain, process and analytical package for each product, while Agila Biotech will be responsible for pre-clinical and Phase 1 development, as well as cGMP manufacturing.  The joint venture will then progress the products through Phase 3 and into commercialization.  Manufacture of the collaboration products will be carried out at Agila Biotech's state-of-the-art manufacturing facility being built with Bio-XCell at Nusajaya, Johor, Malaysia – a 160 acre site comprised of customized biotech facilities.

"One of the global challenges for the future of healthcare is to develop and produce products within the confines of a constrained cost environment," said Dr. Bertrand Liang , CEO at Pfenex. "Biosimilars are and will play an increasingly important role in patient disease management. This venture between Pfenex and Agila Biotech will allow us to leverage our infrastructure for the development of safe, reliable and cost-effective therapies for patients to address unmet medical needs all over the world."

"Successful foray into the biologics space for companies like Agila Biotech would hinge not only on building a state-of-the-art infrastructure and strong technical foundation, but also on creative partnerships such as the one that Agila Biotech has entered into with Pfenex.  This will allow us to not only leverage time and cost advantage of developing products in India and Malaysia, but also serve as a gateway to a vast region in South Asia, South-East Asia and the OIC region currently underserved as a result of the lack of high quality, cost effective biologics," said Dr. Anand Iyer , CEO at Agila Biotech.  Dr. Iyer also noted that its facility in Malaysia represents a strategic move to bolster Agila Biotech's manufacturing presence in the region and tap into unmet global demand for quality biologics at affordable prices.

About Agila Biotech Private Limited (India) / Strides Arcolab Limited: 

Agila Biotech Private Limited, India is a wholly owned subsidiary of Strides Acrolab Limited (Strides). Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of pharmaceutical products.  The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at Strides' website at www.stridesarco.com

About Pfenex Inc.: Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare needs.  Utilizing the company's core technology, Pfenex Expression Technology™ for recombinant protein expression, Pfenex is able to rapidly develop and produce high quality therapeutics. In addition, Pfenex also produces and markets research proteins and reagent proteins for the research and drug development community through its Reagent Proteins division.  For more information please visit www.pfenex.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
2. Epsen Fuller Group Recruits Operations Leader for Global Biotech Firm SOTIO
3. Equatorial Guineas [EG] Ministry of Health convenes in Washington, DC with GB Group Global and TNI Biotech (OTCBB:TNIB) to launch major innovative health solutions and improve pharmaceutical quality for its citizens
4. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
5. Heptares to Present at Boston Biotech BD and Future Leaders in the Biotech Industry Conferences
6. KaloBios to Present at Future Leaders in the Biotech Industry Conference
7. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
8. Regulus to Present at Future Leaders in the Biotech Industry Conference
9. Inovio Pharmaceuticals to Present at BioCenturys "Future Leaders in the Biotech Industry" Conference
10. Financial Assessment of the Global Pharmaceutical and Biotechnology Industry
11. For International Life Sciences, Biotech and Pharmaceutical Events, Top Executives Turn to Global Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 23, 2016 Experts from various ... Medicine and the role of technology in innovative ... The First International Conference of VPS-Penn Medicine opened in ... and presence of Sheikh Nahyan bin Mubarak Al Nahyan, Minister ... Medicine, which helps provide personalized medicine and tailor-made healthcare in ...
(Date:5/23/2016)... -- The global  reprocessed medical devices market ... according to a new study by Grand View Research, ... the lack of centralized support for waste disposal in ... for reprocessed medical devices market. Additionally, the long-term cost-efficiency ... the original device is the high impact rendering driver ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... , ... Tuesday, May 24, Women's Excellence in Wellness, powered by Movestrong will ... Oils, taught by Patti Dolan, RYT, a Young Living Gold Member. The class ... - 7:15pm followed by a small intro to the Oils that can benefit the ...
(Date:5/24/2016)... , ... May 24, 2016 , ... In light of ... aware of the potential of contaminated well water throughout the Houston area. , Heavy ... with well water that’s exposed to contaminants. Residents may not even be aware of ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... "ProText Layouts ... said Christina Austin - CEO of Pixel Film Studios. , ProText Layouts Vol. 3 ... Final Cut Pro X . With ProText Layouts, video editors can create an ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... After graduating ... He spent the next decade in hospitals, on medication, living on Social Security disability ... at the Illness and How I Beat It!” (published by Balboa Press), Alexander shares ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... its highly anticipated, web-based software module. The cutting-edge feature provides end users ... Integration with Izenda’s self-service business intelligence solution and its analytics engine. ...
Breaking Medicine News(10 mins):